Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NS

[News]

Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.

More... (http://www.news-medical.net/news/20120517/Results-from-Boehringer-Ingelheime28099s-LUX-Lung-3-Phase-III-trial-on-stage-IIIB-or-IV-NSCLC.aspx)